Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1092621.RAXLtWAcNM41n6I6nTnGegtQdwuEU7K-9jX19Ccgimpqw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1092621.RAXLtWAcNM41n6I6nTnGegtQdwuEU7K-9jX19Ccgimpqw130_assertion type Assertion NP1092621.RAXLtWAcNM41n6I6nTnGegtQdwuEU7K-9jX19Ccgimpqw130_head.
- NP1092621.RAXLtWAcNM41n6I6nTnGegtQdwuEU7K-9jX19Ccgimpqw130_assertion description "[Any drug including anti-TNF ? blocker which can downregulate the TCR, infiltrated neutrophils, or CD163+ macrophages in the synovial tissue is the rationale for the management of SpA.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1092621.RAXLtWAcNM41n6I6nTnGegtQdwuEU7K-9jX19Ccgimpqw130_provenance.
- NP1092621.RAXLtWAcNM41n6I6nTnGegtQdwuEU7K-9jX19Ccgimpqw130_assertion evidence source_evidence_literature NP1092621.RAXLtWAcNM41n6I6nTnGegtQdwuEU7K-9jX19Ccgimpqw130_provenance.
- NP1092621.RAXLtWAcNM41n6I6nTnGegtQdwuEU7K-9jX19Ccgimpqw130_assertion SIO_000772 23840241 NP1092621.RAXLtWAcNM41n6I6nTnGegtQdwuEU7K-9jX19Ccgimpqw130_provenance.
- NP1092621.RAXLtWAcNM41n6I6nTnGegtQdwuEU7K-9jX19Ccgimpqw130_assertion wasDerivedFrom befree-2016 NP1092621.RAXLtWAcNM41n6I6nTnGegtQdwuEU7K-9jX19Ccgimpqw130_provenance.
- NP1092621.RAXLtWAcNM41n6I6nTnGegtQdwuEU7K-9jX19Ccgimpqw130_assertion wasGeneratedBy ECO_0000203 NP1092621.RAXLtWAcNM41n6I6nTnGegtQdwuEU7K-9jX19Ccgimpqw130_provenance.